Non-antibiotic modulation of small intestinal dysbiosis with oral simethicone as a treatment for patients with disorders of gut-brain interaction: a randomised placebo-controlled trial

None listed

Disorders of Brain Gut Interaction (DGBIs) are extremely common affecting up to onein three Australians. These conditions are chronic, resulting in reduced quality of life for patients and are responsible for substantial health care utilisation. This is largely due to the fact that routinely available treatments do not provide the required symptom relief and long-term improvement of quality of life. In recent times, small intestinal dysbiosis has been identified as a potential cause for DGBI. Small intestinal bacterial dysbiosis refers to an expansion of unfavorable or harmful bacteria in the small intestinal tract. While antibiotics such as rifaximin are proven to improve symptoms in patients with DGBI, there are concerns in relation to antibiotic resistance and antibiotics are not suitable for long term treatment. Previous data suggest that simethicone can be beneficial in DGBI patients and our recent in-vitro data reveal a suppression of growth of bacteria obtained from the small intestine. Thus, we aim to conduct a randomised placebo-controlled trial to test the readily available (over the counter) treatment Simethicone as a means to target the imbalance of bacteria lining the small intestine in patients with DGBI.

No related papers found yet.